MORRIS PLAINS, N.J., Aug. 16, 2007 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported results from a study showing epratuzumab inhibits the activation of B-cells from patients suffering from systemic lupus erythematosus (SLE) but not normal subjects.
